Ixazomib Versus Placebo as Post-Induction Maintenance Therapy in Newly Diagnosed Multiple Myeloma Patients: An Analysis by Age and Frailty Status of the TOURMALINE-MM4 Study

Multiple myeloma (MM) is typically a disease of the elderly, with a median age of 69 years at diagnosis and more than 30% of patients aged ≥ 75 years.1,2 Despite substantial advances in treatment over the past decade,3 elderly patients with MM typically have reduced survival and impaired quality of life (QoL) compared to younger patients, often as a consequence of comorbidities, increased toxicity, and early treatment discontinuation .2,4 Consequently, there remains a substantial unmet need in this patient population for more feasible and tolerable therapies allowing for prolonged treatment.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research